Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more ...

Tarver took the position in late July after the announcement that CDRH’s director of the past 15 years, Jeff Shuren, M.D., ...

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...

Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

Just as Smita Gopinath, Ph.D., was setting up her microbiology and immunology lab at Harvard T.H. Chan School of Public ...

Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...

Noema included other assessments of Tourette symptoms as secondary endpoints. Across the 14 people in the primary analysis, ...

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...